Listed@ASX
Your go-to source for ASX IPO and listed company news, insights and analysis.
Listed@ASX
Your go-to source for ASX IPO and listed company news, insights and analysis.
November 2023
Welcome to the latest insights, news and profiles from the world of listed companies and IPOs.
The ASX listings team has been hard at work, working with industry leaders and listed companies to bring you interesting profiles, trends and updates impacting the sector and those looking to list.
In our lead story, we speak to Leah Weckert, CEO of the Coles Group (ASX:COL) about her vision for the future of the iconic Australian Retailer.
Neuren Pharmaceuticals Limited ASX:NEU
2023 winner of the Australian Growth Company of the Year Award, in the Health and Sciences category - Neuren Pharmaceuticals is building on its success with Daybue securing approval for another important drug.
Sasha Conoplia, Manager, Listings ASX spoke to Raimond Coneliano, CEO and Managing Director of Redox Limited, about the company's recent listing and plans for local and overseas markets.
Watching time: 7:12
For more information contact the ASX Listings team.
Giri Tenneti speaks to Australian Clinical Labs CEO, Melinda McGrath.
Giri Tenneti speaks to Richard White, Founder and CEO of Wisetech Global
James Posnett speaks to Dr. Alan Taylor, Executive Chairman of Clarity Pharmaceuticals
Sign up for Listed@ASX
Your go-to source for ASX IPO and listed company news, insights and analysis - straight to your inbox three time a year.
Subscribe here to hear about upcoming educational events for listed companies and their advisors.
For more information contact the ASX Listings team.
The views, opinions or recommendations of the author in this article are solely those of the author and do not in any way reflect the views, opinions, recommendations, of ASX Limited ABN 98 008 624 691 and its related bodies corporate (“ASX”). ASX makes no representation or warranty with respect to the accuracy, completeness or currency of the content. The content is for educational purposes only and does not constitute financial advice. Independent advice should be obtained from an Australian financial services licensee before making investment decisions. To the extent permitted by law, ASX excludes all liability for any loss or damage arising in any way due to or in connection with the publication of this article, including by way of negligence.